High performance of f-fluorodeoxyglucose positron emission tomography and contrast-enhanced ct in a rapid outpatient diagnostic program for patients with suspected lung cancer

Respiration

Volumn 87, Issue 1, 2014, Pages 32-37

  Brocken, Pepijn ^a   Van Der Heijden, Henricus F M ^a   Dekhuijzen, P N Richard ^a   Peters Bax, Liesbeth ^a   De Geus Oei, Lioe Fee ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic service; Lung cancer; Lung cancer diagnosis; Lung cancer imaging; PET imaging in lung cancer; PET CT fusion imaging; Pulmonary neoplasm; Rapid outpatient diagnostic program

Indexed keywords

AGED; AMBULATORY CARE; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA; TOMOGRAPHY, X-RAY COMPUTED;

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT REFERRAL; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; THERAPY DELAY; THORAX RADIOGRAPHY;

EID: 84895070337     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000347096     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
2. Lewis NR, Le Jeune I, Baldwin DR: Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway. Br J Cancer 2005; 93: 905-908.
3. Conron M, Phuah S, Steinfort D, Dabscheck E, Wright G, Hart D: Analysis of multidisciplinary lung cancer practice. Intern Med J 2007; 37: 18-25.
4. Dransfield MT, Lock BJ, Garver RI: Improving the lung cancer resection rate in the US Department of Veterans Affairs Health System. Clin Lung Cancer 2006; 7: 268-272.
5. Riedel RF, Wang X, McCormack M, Toloza E, Montana GS, Schreiber G, et al: Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. J Thorac Oncol 2006; 1: 692-696.
6. Leary A, Corrigan P: Redesign of thoracic surgical services within a cancer network-using an oncology focus to inform change. Eur J Oncol Nurs 2005; 9: 74-78.
7. Laroche C, Wells F, Coulden R, Stewart S, Goddard M, Lowry E, et al: Improving surgical resection rate in lung cancer. Thorax 1998; 53: 445-449.
8. Murray PV, OBrien ME, Sayer R, Cooke N, Knowles G, Miller AC, et al: The pathway study: Results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer 2003; 42: 283-290.
9. Olsson JK, Schultz EM, Gould MK: Timeliness of care in patients with lung cancer: A systematic review. Thorax 2009; 64: 749-756.
10. Harcourt D, Ambler N, Rumsey N, Cawthorn SJ: Evaluation of a one-stop breast lump clinic: A randomized controlled trial. Breast 1998; 4: 314-319.
11. Dey P, Bundred N, Gibbs A, Hopwood P, Baildam A, Boggis C, et al: Costs and benefits of a one stop clinic compared with a dedicated breast clinic: Randomised controlled trial. BMJ 2002; 324: 507.
12. Ubhi SS, Shaw P, Wright S, Stotter A, Clarke L, Windle R, et al: Anxiety in patients with symptomatic breast disease: Effects of immediate versus delayed communication of results. Ann R Coll Surg Engl 1996; 78: 466-469.
13. Brocken P, Prins JB, Dekhuijzen PNR, Van Der Heijden HFM: The faster the better-A systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology 2012; 21: 1-10.
14. De Wever W, Stroobants S, Coolen J, Verschalken JA: Integrated PET/CT in the staging of nonsmall cell lung cancer: Technical aspects and clinical integration. Eur Respir J 2009; 33: 201-212.
15. Subedi N, Scarsbrook A, Darby M, Korde K, Mc Shane P, Muers MF: The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. Lung Cancer 2009; 64: 301-307.
16. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al: Staging of non-smallcell lung cancer with integrated positronemission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507.
17. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al: Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging. Radiology 2003; 229: 526-533.
18. Aukema TS, Valdés Olmos RA, Klomp HM, Teertstra HJ, Belderbos JS, Vogel WV, et al: Evaluation of 18 F-FDG PET-CT for differentiation of pulmonary pathology in an approach of outpatient fast track assessment. J Thorac Oncol 2009; 4: 1226-1230.
19. Mountain CF: Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
20. ORourke N, Edwards R: Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 2000; 12: 141-144.
21. Annakkaya AN, Arbak P, Balbay O, Bilgin C, Erbas M, Bulut I: Effect of symptom-to-treatment interval on prognosis in lung cancer. Tumori 2007; 93: 61-67.
22. Devbhandari MP, Soon SY, Quennell P, Barber P, Krysiak P, Shah R, et al: UK waiting time targets in lung cancer treatment: Are they achievable Results of a prospective tracking study. J Cardiothorac Surg 2007; 2: 5.
23. Koyi H, Hillerdal G, Branden E: Patients and doctors delays in the diagnosis of chest tumors. Lung Cancer 2002; 35: 53-57.
24. Salomaa ER, Sallinen S, Hiekkanen H, Liippo K: Delays in the diagnosis and treatment of lung cancer. Chest 2005; 128: 2282-2288.
25. Yilmaz A, Damadoglu E, Salturk C, Okur E, Tuncer LY, Halezeroglu S: Delays in the diagnosis and treatment of primary lung cancer: Are longer delays associated with advanced pathological stage Ups J Med Sci 2008; 113: 287-296.
26. Lo DS, Zeldin RA, Skrastins R, Fraser IM, Newman H, Monavvari A, et al: Time to treat: A system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. J Thorac Oncol 2007; 2: 1001-1006.
27. Neal RD, Allgar VL, Ali N, Leese B, Heywood P, Proctor G, et al: Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: Comparison between diagnostic routes. Br J Gen Pract 2007; 57: 212-219.
28. Ozlu T, Bulbul Y, Oztuna F, Can G: Time course from first symptom to the treatment of lung cancer in the Eastern Black Sea Region of Turkey. Med Princ Pract 2004; 13: 211-214.
29. Liberman M, Liberman D, Sampalis JS, Mulder DS: Delays to surgery in non-small-cell lung cancer. Can J Surg 2006; 49: 31-36.
30. Kesson E, Bucknall CE, McAlpine LG, Milroy R, Hole D, Vernon DR, et al: Lung cancer-management and outcome in Glasgow, 1991-92. Br J Cancer 1998; 78: 1391-1395.
31. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001; 285: 914-924.
32. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al: High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 287-293.
33. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BR, et al: Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1943-1951.
34. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM: Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology in 2000 (in German). Pneumologie 2001; 55: 367-377.
35. Heo E, Yang S, Yoo C, Han SK, Shim YS, Kim YW: Impact of 18 F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer. Respirology 2010; 15: 1174-1178.
36. Agress H, Cooper B: Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: Histopathologic comparison. Radiology 2004; 230: 417-422.
37. Schreyögg J, Weller J, Stargardt T, Herrmann K, Bluemel C, Dechow T, et al: Cost-effectiveness of hybrid PET/CT for staging of nonsmall cell lung cancer. J Nucl Med 2010; 51: 1668-1675.
38. Fisher B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al: Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009; 361: 32-39.